These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38400590)

  • 41. Sickle Cell Disease: A Brief Update.
    Azar S; Wong TE
    Med Clin North Am; 2017 Mar; 101(2):375-393. PubMed ID: 28189177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A rapid paper-based test for quantifying sickle hemoglobin in blood samples from patients with sickle cell disease.
    Piety NZ; Yang X; Lezzar D; George A; Shevkoplyas SS
    Am J Hematol; 2015 Jun; 90(6):478-82. PubMed ID: 25689370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of HbS levels upon the hematological and clinical characteristics of sickle cell trait.
    Kennedy AP; Walsh DA; Nicholson R; Adams JG; Steinberg MH
    Am J Hematol; 1986 May; 22(1):51-4. PubMed ID: 3953566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quercetin Completely Ameliorates Hypoxia-Reoxygenation-Induced Pathophysiology Severity in NY1DD Transgenic Sickle Mice: Intrinsic Mild Steady State Pathophysiology of the Disease in NY1DD Is Also Reversed.
    Thangaswamy S; Branch CA; Ambadipudi K; Acharya SA
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Common gynecological challenges in adolescents with sickle cell disease.
    Stimpson SJ; Rebele EC; DeBaun MR
    Expert Rev Hematol; 2016; 9(2):187-96. PubMed ID: 26613137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oxidative stress in sickle cell disease; more than a DAMP squib.
    van Beers EJ; van Wijk R
    Clin Hemorheol Microcirc; 2018; 68(2-3):239-250. PubMed ID: 29614635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sickle cell biomechanics.
    Barabino GA; Platt MO; Kaul DK
    Annu Rev Biomed Eng; 2010 Aug; 12():345-67. PubMed ID: 20455701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease.
    Beckman JD; Abdullah F; Chen C; Kirchner R; Rivera-Rodriguez D; Kiser ZM; Nguyen A; Zhang P; Nguyen J; Hebbel RP; Belcher JD; Vercellotti GM
    Front Immunol; 2020; 11():613278. PubMed ID: 33542720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insights provided by a comparison of impaired deformability with erythrocyte oxidative stress for sickle cell disease.
    Barodka VM; Nagababu E; Mohanty JG; Nyhan D; Berkowitz DE; Rifkind JM; Strouse JJ
    Blood Cells Mol Dis; 2014 Apr; 52(4):230-5. PubMed ID: 24246527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single Molecule Studies of the Diffusion of Band 3 in Sickle Cell Erythrocytes.
    Spector J; Kodippili GC; Ritchie K; Low PS
    PLoS One; 2016; 11(9):e0162514. PubMed ID: 27598991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot study of manual chronic partial exchange transfusion in children with sickle disease.
    Aloni MN; Lê PQ; Heijmans C; Huybrechts S; Devalck C; Azzi N; Ngalula-Mujinga M; Ferster A
    Hematology; 2015 Jun; 20(5):284-8. PubMed ID: 25133935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.
    Detterich JA; Liu H; Suriany S; Kato RM; Chalacheva P; Tedla B; Shah PM; Khoo MC; Wood JC; Coates TD; Milne GL; Oh JY; Patel RP; Forman HJ
    Free Radic Biol Med; 2019 Sep; 141():408-415. PubMed ID: 31279092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathophysiological characterization of the Townes mouse model for sickle cell disease.
    Alvarez-Argote J; Dlugi TA; Sundararajan T; Kleynerman A; Faber ML; McKillop WM; Medin JA
    Transl Res; 2023 Apr; 254():77-91. PubMed ID: 36323381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sickle cell disease, vasculopathy, and therapeutics.
    Kassim AA; DeBaun MR
    Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.
    Conran N; De Paula EV
    Haematologica; 2020 Oct; 105(10):2380-2390. PubMed ID: 33054078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A modified transfusion program for prevention of stroke in sickle cell disease.
    Cohen AR; Martin MB; Silber JH; Kim HC; Ohene-Frempong K; Schwartz E
    Blood; 1992 Apr; 79(7):1657-61. PubMed ID: 1558963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of sickle hemoglobin polymerization and membrane properties on deformability of sickle erythrocytes in the microcirculation.
    Dong C; Chadwick RS; Schechter AN
    Biophys J; 1992 Sep; 63(3):774-83. PubMed ID: 1420913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.